Ludovica Pasca1, Valentina De Giorgis1,2, Joyce Ann Macasaet3, Claudia Trentani4, Anna Tagliabue4, Pierangelo Veggiotti5,6. 1. Department of Child Neurology and Psychiatry, IRCCS "C. Mondino" National Neurological Institute, Pavia, Italy. 2. Brain and Behaviour Department, University of Pavia, Via Mondino, 2, 27100, Pavia, Italy. 3. Makati Medical Center, Manila, Philippines. 4. Human nutrition and eating disorder center, department of public health, experimental and forensic medicine, University of Pavia, Pavia, Italy. 5. Department of Child Neurology and Psychiatry, IRCCS "C. Mondino" National Neurological Institute, Pavia, Italy. pierangelo.veggiotti@unipv.it. 6. Brain and Behaviour Department, University of Pavia, Via Mondino, 2, 27100, Pavia, Italy. pierangelo.veggiotti@unipv.it.
Abstract
UNLABELLED: Ketogenic diet is an established and effective non-pharmacologic treatment for drug-resistant epilepsy. Ketogenic diet represents the treatment of choice for GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. Infantile spasms, Dravet syndrome and myoclonic-astatic epilepsy are epilepsy syndromes for which ketogenic diet should be considered early in the therapeutic pathway. Recently, clinical indications for ketogenic diet have been increasing, as there is emerging evidence regarding safety and effectiveness. Specifically, ketogenic diet response has been investigated in refractory status epilepticus and encephalopathy with status epilepticus during sleep. New targets in neuropharmacology, such as mitochondrial permeability transition, are being studied and might lead to using it effectively in other neurological diseases. But, inefficient connectivity and impaired ketogenic diet proposal limit ideal availability of this therapeutic option. Ketogenic diet in Italy is not yet considered as standard of care, not even as a therapeutic option for many child neurologists and epileptologists. CONCLUSIONS: The aim of this review is to revisit ketogenic diet effectiveness and safety in order to highlight its importance in drug-resistant epilepsy and other neurological disorders. WHAT IS KNOWN: • Ketogenic diet efficacy is now described in large case series, with adequate diet compliance and side effects control. • Ketogenic diet is far from being attempted as a first line therapy. Its availability varies worldwide. What is New: • New pharmacological targets such as mitochondrial permeability transition and new epileptic syndromes and etiologies responding to the diet such as refractory status epilepticus are being pointed out. • Ketogenic diet can function at its best when used as a tailor-made therapy. Fine tuning is crucial.
UNLABELLED: Ketogenic diet is an established and effective non-pharmacologic treatment for drug-resistant epilepsy. Ketogenic diet represents the treatment of choice for GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. Infantile spasms, Dravet syndrome and myoclonic-astatic epilepsy are epilepsy syndromes for which ketogenic diet should be considered early in the therapeutic pathway. Recently, clinical indications for ketogenic diet have been increasing, as there is emerging evidence regarding safety and effectiveness. Specifically, ketogenic diet response has been investigated in refractory status epilepticus and encephalopathy with status epilepticus during sleep. New targets in neuropharmacology, such as mitochondrial permeability transition, are being studied and might lead to using it effectively in other neurological diseases. But, inefficient connectivity and impaired ketogenic diet proposal limit ideal availability of this therapeutic option. Ketogenic diet in Italy is not yet considered as standard of care, not even as a therapeutic option for many child neurologists and epileptologists. CONCLUSIONS: The aim of this review is to revisit ketogenic diet effectiveness and safety in order to highlight its importance in drug-resistant epilepsy and other neurological disorders. WHAT IS KNOWN: • Ketogenic diet efficacy is now described in large case series, with adequate diet compliance and side effects control. • Ketogenic diet is far from being attempted as a first line therapy. Its availability varies worldwide. What is New: • New pharmacological targets such as mitochondrial permeability transition and new epileptic syndromes and etiologies responding to the diet such as refractory status epilepticus are being pointed out. • Ketogenic diet can function at its best when used as a tailor-made therapy. Fine tuning is crucial.
Authors: A G Christina Bergqvist; Joan I Schall; Paul R Gallagher; Avital Cnaan; Virginia A Stallings Journal: Epilepsia Date: 2005-11 Impact factor: 5.864
Authors: Raphael Johannes Morscher; Sepideh Aminzadeh-Gohari; René Gunther Feichtinger; Johannes Adalbert Mayr; Roland Lang; Daniel Neureiter; Wolfgang Sperl; Barbara Kofler Journal: PLoS One Date: 2015-06-08 Impact factor: 3.240
Authors: Pamela N Klassen; Benjamin A Goldenberg; Pascal Lambert; Kathy Vagianos; Christina A Kim Journal: Support Care Cancer Date: 2020-02-23 Impact factor: 3.603
Authors: Stjepana Kovac; Albena T Dinkova Kostova; Alexander M Herrmann; Nico Melzer; Sven G Meuth; Ali Gorji Journal: Int J Mol Sci Date: 2017-09-08 Impact factor: 5.923
Authors: Samira Ait-El-Mkadem; Manal Dayem-Quere; Mirjana Gusic; Annabelle Chaussenot; Sylvie Bannwarth; Bérengère François; Emmanuelle C Genin; Konstantina Fragaki; Catharina L M Volker-Touw; Christelle Vasnier; Valérie Serre; Koen L I van Gassen; Françoise Lespinasse; Susan Richter; Graeme Eisenhofer; Cécile Rouzier; Fanny Mochel; Anne De Saint-Martin; Marie-Thérèse Abi Warde; Monique G M de Sain-van der Velde; Judith J M Jans; Jeanne Amiel; Ziga Avsec; Christian Mertes; Tobias B Haack; Tim Strom; Thomas Meitinger; Penelope E Bonnen; Robert W Taylor; Julien Gagneur; Peter M van Hasselt; Agnès Rötig; Agnès Delahodde; Holger Prokisch; Sabine A Fuchs; Véronique Paquis-Flucklinger Journal: Am J Hum Genet Date: 2016-12-15 Impact factor: 11.025